ArticleScientific reports2026
Clinical features, outcomes, and prognostic factors of lymphocyte-depleted classical Hodgkin lymphoma: a population-based SEER analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphocyte-depleted classical Hodgkin lymphoma (LD-cHL) is a rare histologic subtype of classical Hodgkin lymphoma. This population-based study aimed to describe the clinical characteristics and prognostic factors of LD-cHL using data from the SEER registry.LD-cHL patients were older (median age 55 years, IQR: 37-72) than those with other subtypes (median age 38 years, IQR: 25-58; p < 0.001). They were more likely to present with advanced disease (35% Stage IV [N = 159] vs. 15% [N = 6,136]; p < 0.001). B symptoms were also more frequent in LD-cHL (67.8%, N = 307 vs. 54.5%, N = 23,025; p < 0.001).The 5-year overall survival rate for LD-cHL was 51.2% (95% CI: 46.7-56.2), lower than the 81.1% (95% CI: 80.7-81.5) observed in other subtypes. Random survival forest analysis identified age (variable importance: 0.31) and chemotherapy receipt (0.10) as the variables with the highest importance scores. Age stratification showed 5-year overall survival rates of 78.5% (95% CI: 72.5-85.1) for patients < 40 years, 43.3% (95% CI: 36.4-51.6) for those aged 40-60 years, and 15.6% (95% CI: 9.6-25.2) for those > 60 years. Chemotherapy receipt was associated with higher survival rates across all age groups.In subgroup analyses limited to patients who received chemotherapy, LD-cHL remained associated with inferior survival compared with other subtypes. Lymphoma-specific survival analysis yielded 5-year rates of 88.9%, 84.3%, and 60.5% in the < 40, 40-60, and > 60 years groups, respectively.This study confirms that LD-cHL is associated with older age, advanced stage at presentation, and relatively poor survival in real-world settings. Further studies with central pathological review and more detailed clinical data are needed to improve the understanding and management of this rare subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.